GlycoMimetics' GMI-1271 an Orphan Drug for blood cancer

• The FDA designates GlycoMimetics' (GLYC +6.2%) investigational GMI-1271 an Orphan Drug for the treatment of patients with acute myeloid leukemia.
• GMI-1271, currently in Phase 1/2 development, is an E-selectin antagonist. E-selectin (E - endothelial) is a cell adhesion molecule that plays a key role in inflammation.
• Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.